CBD shows promise for seizures and anxiety in children with epilepsy

This preliminary study examined how Epidiolex (pharmaceutical-grade CBD), an FDA-approved medication, affects children with refractory epilepsy who also experience anxiety—a common co-occurring condition. Over 4-6 weeks, 73% of caregivers reported improvements in both anxiety and seizure frequency, with participants also showing better sleep quality and minimal side effects. The research highlights an important clinical gap: while anxiety frequently accompanies childhood epilepsy, few treatment options effectively address both conditions simultaneously. Epidiolex appears to offer promise as a dual-benefit therapy.

The study also investigated the biological mechanisms behind CBD's effects by measuring circulating endocannabinoids—the body's natural cannabis-like molecules—and related lipid biomarkers. Researchers found that plasma 2-arachidonoylglycerol (2-AG), a key endocannabinoid, increased from baseline to study end, with greater increases in children who started with lower baseline levels. The presence of 7-hydroxycannabidiol (7-OH-CBD), a CBD metabolite, confirmed that the drug was reaching the bloodstream effectively. These findings suggest CBD's anxiolytic and anti-seizure benefits may work through the body's endocannabinoid system.

Though preliminary with only 12 participants, this research opens important questions about how pharmaceutical-grade CBD can address multiple symptoms in pediatric epilepsy. The biomarker data provides mechanistic insight into how CBD interacts with the endocannabinoid system, potentially influencing both seizure control and anxiety relief. Larger clinical trials are needed to confirm these findings, but the results suggest CBD may be a valuable option for children dealing with the dual burden of seizures and anxiety.